Veradermics announced positive Phase 2 results for VDPHL01 in female pattern hair loss, showing early onset and durable hair growth with a favorable safety profile. Both dosing regimens produced meaningful hair-count gains and strong patient-reported improvements, with pivotal results anticipated in 2026–2027. MANE’s exposure to this evolving oral-hair-loss landscape could influence its valuation and strategy.
Veradermics Inc. (NYSE:MANE) announced positive results from its Phase 2/3 trial of VDPHL01, which may become the first oral FDA-approved treatment for hair loss in nearly 30 years. With 79.3% and 86.0% of patients reporting improved hair coverage, this positions the company favorably in a lucrative market, driving a significant share price surge.
